affron®, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study
EntityUAM. Departamento de Química Física Aplicada; Instituto de Investigación en Ciencias de la Alimentación (CIAL)
10.1016/j.jad.2018.02.070Journal of Affective Disorders 232 (2018): 349-357
ISSN0165-0327 (print); 1573-2517 (online)
Funded byThis study was funded by Pharmactive Biotech Products SL. Pharmactive Biotech Products was not involved in the design of the research, analysis of data, or in the writing of the report. The authors gratefully acknowledge Pharmactive Biotech Products SL Company for funding the project and supplying affron® and LIPA Pharmaceuticals for the preparation of the tablets
SubjectsAnxiety; Clinical trial; Depression; Saffron extract; Teenager; Youth; Química
Rights© 2018 Crown Copyright published by Elsevier
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
Background: Saffron has antidepressant and anxiolytic effects in adults with mild-to-moderate depression. However, this is the first study examining its mood-related effects in teenagers. Methods: In this 8-week, randomised, double-blind, placebo-controlled study, youth aged 12–16 years, with mild-to-moderate anxiety or depressive symptoms were given tablets containing placebo or a saffron extract (affron®, 14 mg b.i.d). The youth and parent versions of the Revised Child Anxiety and Depression Scale (RCADS) were used as outcome measures. Results: 80 participants were enrolled and 68 completed the study. Based on youth self-reports, affron®was associated with greater improvements in overall internalising symptoms (p = 0.049), separation anxiety (p = 0.003), social phobia (p = 0.023), and depression (p = 0.016). Total internalising scores decreased by an average of 33% compared to 17% in the placebo group (p = 0.029). However, parental reports of improvements were inconsistent as mean improvements in RCADS scores were greater in the saffron group (40% vs 26%) (p = 0.026), although no other significant differences were identified. affron®was well-tolerated and there was a trend of reduced headaches in participants on the active treatment. Limitations: The use of a self-report instrument, limited study duration, single treatment dose, and non-clinical sample used in this study limit the generalisability of study findings. Conclusion: The administration of a standardised saffron extract (affron®) for 8 weeks improved anxiety and depressive symptoms in youth with mild-to-moderate symptoms, at least from the perspective of the adolescent. However, these beneficial effects were inconsistently corroborated by parents.
Google Scholar:Lopresti, Adrian L. - Drummond, Peter D. - Inarejos-García, Antonio M. - Prodanov Prodanov, Marin
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Methylphenidate in mania project (MEMAP): Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate Kluge, Michael; Hegerl, Ulrich; Sander, Christian; Dietzel, Jens; Mergl, Roland; Bitter, István; Demyttenaere, Koen; Gusmão, Ricardo M.; González-Pinto, Ana María; Pérez-Solà, Victoŕ; Vieta, Eduard; Juckel, Georg; Zimmermann, Ulrich S.; Bauer, Michael S.; Sienaert, Pascal A.; Quintão, Sónia Dos Reis; Edel, Marc Andreas; Bolyos, Csilla; Ayuso Mateos, José Luis; López-García, Pilar
Anti-influenza virus activity of the elenolic acid rich olive leaf (Olea europaea L.) extract Isenolic
A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial